Humanigen

Humanigen, Inc. is a clinical-stage biopharmaceutical company. engages in the development of cell and gene therapies for the treatment of cancers through novel human granulocyte-macrophage colony-stimulating factor neutralization and gene-knockout platforms. The company was founded by Jeng-Horng Her & Robert F. Balint on March 15, 2000 and is headquartered in Essex County, NJ.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Humanigen is a biopharmaceutical company that uses its biologic capabilities and its proprietary platform technology to develop first-in-class human antibody therapeutics. It focuses on preventing the serious and potentially life-threatening side-effects associated with chimeric antigen receptor T-cell (CAR-T) therapy. Its pipeline includes programs such as Lenzilumab, Ifabotuzumab, and HGen005.

LEAD PLAINTIFF DEADLINE IS OCTOBER 25, 2022 NEW YORK , Sept. 2, 2022 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP  announces that  a federal securities class action lawsuit announces that a class action lawsuit has been filed against Humanigen, Inc. ("Humanigen" or the "Company") (NASDAQ: HGEN) in the United States District Court for the District of New Jersey on behalf of all persons and entities who purchased or otherwise acquired Humanigen securities between May28, 2021 and July 12, 2022, both dates inclusive (the "Class Period").

HUMANIGEN, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the District of New Jersey against Humanigen, Inc.

NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Humanigen, Inc. (“Humanigen” or “the Company”) (NASDAQ: HGEN) and certain of its officers on behalf of all persons and entities that purchased, or otherwise acquired Humanigen securities between May 28, 2021, and July 12, 2022, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/

Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Humanigen, Inc. (HGEN) Investors of Class Action and Encourages Investors to Actively Participate

Los Angeles, California--(Newsfile Corp. - September 2, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humanigen, Inc. ("Humanigen" or "the Company") (NASDAQ: HGEN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Humanigen, Inc. with Losses of $100,000 to Contact the Firm

Did you lose money on investments in Humanigen? If so, please visit Humanigen, Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your rights.

HUMANIGEN, INC. (HGEN) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Humanigen, Inc. (HGEN)

Cellectis SA

Omega Therapeutics

Former Novartis Veteran Brings Deep Expertise in Drug Development and Commercialization CAMBRIDGE, Mass. , Sept. 1, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first systematic approach to using mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing™ platform, today announced the appointment of Rainer Boehm as an independent director to its Board of Directors.

Omega Therapeutics Announces Appointment of Rainer Boehm to its Board of Directors

New York, New York--(Newsfile Corp. - August 31, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Humanigen, Inc. (NASDAQ: HGEN) between May 28, 2021 and July 12, 2022, both dates inclusive (the "Class Period"). If you wish to serve as lead plaintiff, you must move the Court no later than October 25, 2022.

HGEN Equity Notice: ROSEN, Global Investor Counsel, Encourages Humanigen, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - HGEN

NEW YORK , Aug. 31, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Humanigen, Inc. (NASDAQ: HGEN) between May 28, 2021 and July 12, 2022, both dates inclusive (the "Class Period"). If you wish to serve as lead plaintiff, you must move the Court no later than October 25, 2022.

HGEN INVESTOR ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Humanigen, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - HGEN

SAN DIEGO--(BUSINESS WIRE)---- $HGEN #COVID19--Humanigen, Inc. (HGEN) Overstated the Clinical and Commercial Prospects of its Lead Drug Candidate

HGEN Shareholder Update: Robbins LLP Reminds Investors of Class Action Filed Against Humanigen, Inc. (HGEN)

NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Humanigen, Inc. (“Humanigen” or the “Company”) (NASDAQ: HGEN) in the United States District Court for the District of New Jersey on behalf of all persons and entities who purchased or otherwise acquired Humanigen securities between May 28, 2021 and July 12, 2022, both dates inclusive (the “Class Period”). Investors have unt

HUMANIGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Humanigen, Inc. and Encourages Investors to Contact the Firm

Humanigen, Inc. Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Humanigen, Inc. (HGEN)

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Humanigen, Inc. (NASDAQ: HGEN) between May 28, 2021 and July 12, 2022, both dates inclusive (the “Class Period”). If you wish to serve as lead plaintiff, you must move the Court no later than October 25, 2022. SO WHAT: If you purchased Humanigen securities during the Class Period you may be entitled to compensation without

EQUITY ALERT: Rosen Law Firm Encourages Humanigen, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – HGEN

LOS ANGELES--(BUSINESS WIRE)---- $HGEN #HGEN--The Schall Law Firm Encourages Investors in Humanigen, Inc. with Losses of $100,000 to Contact the Firm

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Humanigen, Inc. with Losses of $100,000 to Contact the Firm

Source: shutterstock.com/PhotobyTawat Humanigen (NASDAQ: HGEN ) stock is heading lower on Monday as investors react to a delisting notice from the Nasdaq Exchange. According to a filing with the U.S. Securities and Exchange Commission (SEC), HGEN stock has been unable to maintain the minimum bid price of $1 per share to remain on the market.

Why Is Humanigen (HGEN) Stock Down 16% Today?

Humanigen Inc. (HGEN) delivered earnings and revenue surprises of -26.47% and 0.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Humanigen Inc. (HGEN) Reports Q2 Loss, Lags Revenue Estimates

SHORT HILLS, N.J.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on developing lenzilumab (LENZ®), a first-in class antibody that neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), today reported financial results for the second quarter and six months ended June 30, 2022. “We have made excellent progress on the strategic realignment announced in July. We have increased the number of sites for the PREACH-M st

Humanigen Reports Second Quarter 2022 Financial Results

Humanigen Inc. (HGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Humanigen Inc. (HGEN) Report Negative Q2 Earnings? What You Should Know

Short Hills, New Jersey--(Newsfile Corp. - July 26, 2022) - Humanigen, Inc. (NASDAQ: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on developing lenzilumab, a first-in class antibody that neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), today announced a strategic realignment of its pipeline and resources to achieve key clinical milestones. The Company plans to accelerate the development of lenzilumab in chronic myelomonocytic leukemia ("CMML"), a rare blood cancer, for which the PREACH-M study is already underway.

Humanigen Implements Strategic Realignment of Pipeline and Resources to Achieve Key Clinical Milestones

Los Angeles, California--(Newsfile Corp. - July 20, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Humanigen, Inc. ("Humanigen" or "the Company") (NASDAQ: HGEN) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Humanigen disclosed on July 13, 2022, that its lenzilumab drug failed to...

ONGOING INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Humanigen, Inc. with Losses of $100,000 to Contact the Firm

San Diego, California--(Newsfile Corp. - July 19, 2022) - Shareholder rights law firm Johnson Fistel, LLP (www.JohnsonFistel.com) is investigating whether Humanigen, Inc. ("Humanigen" or "the Company") (NASDAQ: HGEN), any of its executive officers, or others violated securities laws by misrepresenting or failing to timely disclose material, adverse information to investors. The investigation focus on investors' losses and whether they may be recovered under the federal securities laws.What if I purchased Humanigen common stock? If you...

HGEN Alert: Johnson Fistel, Globally-Recognized Law Firm, Investigates Humanigen

The NIAID's ACTIV-5/BET-B study evaluating Humanigen's (HGEN) lenzilumab plus remdesivir in hospitalized COVID-19 patients fails to meet the primary endpoint. Stock down.

Humanigen (HGEN) Plunges as COVID Study Fails to Meet Goal

HC Wainwright downgraded Humanigen Inc (NASDAQ: HGEN) to Neutral from Buy and removed the price target based on the removal of COVID-19 from lenzilumab projections and the lack of near-term catalysts beyond COVID-19 that could potentially drive the shares. The analyst looks to.

HC Wainwright Downgrades Humanigen On Disappointing COVID-19 Study - What's Next

Humanigen (HGEN) stock is falling hard on Wednesday following the release of preliminary results from a Covid-19 clinical trial. The post Why Is Humanigen (HGEN) Stock Plunging 79% Today?

Why Is Humanigen (HGEN) Stock Plunging 79% Today?

Shares of Humanigen Inc. plunged 67.9% in premarket trading on Wednesday, the day after the company said a National Institutes of Health clinical trial testing lenzilumab and Gilead Sciences Inc.'s Veklury in hospitalized COVID-19 patients did not produce the same benefit as it did in previous studies. Humanigen's stock is down 19.6% this year, while the S&P 500 has declined 19.9%.

Humanigen's stock tumbles 67% after sharing new clinical data for its COVID-19 treatment

Humanigen Inc (NASDAQ: HGEN) has been informed of preliminary topline results from the ACTIV-5/BET-B trial evaluating lenzilumab plus remdesivir versus placebo plus remdesivir in hospitalized COVID-19 patients.  The trial did not achieve statistical significance on the primary.

Humanigen's Lenzilumab Disappoints In NIH-Backed COVID-19 Study

SHORT HILLS, N.J.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”) has been informed of preliminary topline results from the National Institute of Allergy and Infectious Diseases' (NIAID) ACTIV-5/BET-B trial evaluating lenzilumab plus remdesivir versus placebo plus remdesivir in hospitalized COVID-19 patients. The trial did not achieve statistical significance on the primary endpoint, which was defined as the proportion of patients with baseline CRP

News for Humanigen Stock (HGEN)